Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,579,689 papers from all fields of science
Search
Sign In
Create Free Account
Selegiline
Known as:
L-Deprenyl
, (-)-selegiline
, Selegiline [Chemical/Ingredient]
Expand
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
29 relations
Narrower (10)
4-fluorodeprenyl
Deprenyl
E-250
Eldepryl
Expand
Alzheimer's Disease
Attention deficit hyperactivity disorder
Depressive disorder
Drug Allergy
Expand
Broader (3)
Antiparkinson Agents
Monoamine Oxidase Inhibitors
Neuroprotective Agents
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Future of neuroprotection in Parkinson's disease.
M. Naoi
,
W. Maruyama
Parkinsonism & Related Disorders
2001
Corpus ID: 32084117
Highly Cited
2000
Highly Cited
2000
Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes.
I. Mizuta
,
M. Ohta
,
+4 authors
S. Kuno
Biochemical and Biophysical Research…
2000
Corpus ID: 35843877
We investigated the effects of selegiline and desmethylselegiline on synthesis of neurotrophic factors in cultured mouse…
Expand
1998
1998
l-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats
S. Thyagarajan
,
K. Madden
,
J. C. Kalvass
,
S. Dimitrova
,
S. Felten
,
D. Felten
Journal of Neuroimmunology
1998
Corpus ID: 35195240
Review
1997
Review
1997
Parkinson's disease: prospects for improved drug therapy.
J. Hagan
,
D. Middlemiss
,
P. Sharpe
,
G. Poste
TIPS - Trends in Pharmacological Sciences
1997
Corpus ID: 23350860
Highly Cited
1991
Highly Cited
1991
Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease
J. Rinne
,
M. Röyttä
,
L. Paljärvi
,
J. Rummukainen
,
U. Rinne
Neurology
1991
Corpus ID: 35937582
We studied the effect of selegiline (deprenyl) treatment on the number of Lewy bodies and neuron counts in the substantia nigra…
Expand
Highly Cited
1989
Highly Cited
1989
Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier.
H. L. Wiener
,
A. Hashim
,
A. Lajtha
,
H. Sershen
European Journal of Pharmacology
1989
Corpus ID: 2251016
Highly Cited
1988
Highly Cited
1988
Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide Is Mediated by Brain Monoamine Oxidase B
P. J. Varebeke
,
R. Cavalier
,
M. David‐Remacle
,
M. Youdim
Journal of Neurochemistry
1988
Corpus ID: 29788910
Abstract: Milacemide (2‐n‐pentylaminoacetamide) is a secondary monoamine that in the brain is converted to glycinamide and…
Expand
1988
1988
Amino Acid Availability and Brain Function in Health and Disease
G. Huether
NATO ASI Series
1988
Corpus ID: 43288869
Until the early seventies, it was generally believed that normal brain function would be unaffected by the metabolic changes…
Expand
Highly Cited
1980
Highly Cited
1980
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
John H. Mann
,
Samuel Gershon
Life Science
1980
Corpus ID: 30599903
Highly Cited
1980
Highly Cited
1980
The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations.
J. Lai
,
T. Leung
,
J. Guest
,
L. Lim
,
A. Davison
Biochemical Pharmacology
1980
Corpus ID: 12833314
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE